

AD \_\_\_\_\_

Award Number: DAMD17-01-1-0524

TITLE: Identification of Target Genes of the Steroid Hormone Receptor Co-Activator AIB1 (Amplified in Breast Cancer 1)

PRINCIPAL INVESTIGATOR: Heinz-Joachim List, Ph.D.

CONTRACTING ORGANIZATION: Georgetown University  
Washington, DC 20057

REPORT DATE: June 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved  
OMB No. 074-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED	
	June 2002	Final (15 May 01 - 14 May 02)	
4. TITLE AND SUBTITLE  Identification of Target Genes of the Steroid Hormone Receptor Co-Activator AIB1 (Amplified in Breast Cancer 1)			5. FUNDING NUMBERS  DAMD17-01-1-0524
6. AUTHOR(S): Heinz-Joachim List, Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Georgetown University Washington, DC 20057  E-Mail: Listh@georgetown.edu			8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES			20030502 132
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE
13. Abstract (Maximum 200 Words) <i>(abstract should contain no proprietary or confidential information)</i>  Steroid hormones play pivotal roles in the control of breast cancer proliferation and differentiation. The biological effects of these hormones are mediated through intracellular receptor proteins, e.g. the estrogen receptor (ER) and through interaction of these receptors with specific co-activators. Of particular interest is the co-activator AIB1 (amplified in breast cancer 1). The AIB1 gene was found to be amplified in 5-10% of primary breast tumor specimens and AIB1 mRNA was found to be overexpressed in many breast tumor specimens. It has been shown that AIB1 promotes the activity of the ER and the growth of human MCF-7 breast cancer cells. Our hypothesis was that AIB1 determines activation or repression of a vast number of genes important for breast cancer growth. Our goal in this study was to identify these target genes.  We generated MCF-7 breast cancer cell lines in which we could specifically downregulate AIB1 levels utilizing tetracycline-regulatable ribozymes directed against AIB1. Utilizing these cells, we found, after estrogen and growth factor stimulation, that gene expression profiles differed significantly from cells with high AIB1 levels when compared to cells with significantly reduced AIB1 levels by microarray analysis. Several of the identified AIB1 target genes might have implications for breast cancer therapy.			
14. SUBJECT TERMS breast cancer			15. NUMBER OF PAGES 12
			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

NSN 7540-01-280-5500

## **Table of Contents**

<b>Cover.....</b>	<b>1</b>
<b>SF 298.....</b>	<b>2</b>
<b>Table of Contents.....</b>	<b>3</b>
<b>Introduction.....</b>	<b>4</b>
<b>Body.....</b>	<b>4</b>
<b>Key Research Accomplishments.....</b>	<b>8</b>
<b>Reportable Outcomes.....</b>	<b>9</b>
<b>Conclusions.....</b>	<b>9</b>
<b>References.....</b>	<b>9</b>
<b>Appendices .....</b>	<b>12</b>

## **Introduction**

Small fat soluble hormones such as steroids, retinoids and vitamin D3 play pivotal roles in the control of breast cancer proliferation and differentiation. The biological effects of these molecules are mediated through intracellular receptor proteins. Estrogens stimulate proliferation of estrogen receptor (ER) positive breast cancer cells and the ER status of a breast tumor is predictive of the outcome of the disease. Therapy (such as tamoxifen) targeted at reducing the estrogenic stimulus to the breast has been shown to be effective. Conversely retinoids and vitamin D3 are strongly growth inhibitory in breast tumor cells and analogues of these compounds are currently being tested for efficacy in breast cancer. Recently the discovery of proteins known as steroid receptor co-activators has led to another level of complexity to our understanding of how hormones exert their effects [1,2]. Of particular interest is the co-activator **AIB1 (amplified in breast cancer 1)**, which interacts with the estrogen receptor (ER) [3]. The AIB1 gene was found to be amplified in 5-10% of primary breast tumor specimens, AIB1 mRNA was found to be overexpressed in many breast tumor specimens and AIB1 protein expression is significantly elevated in about 10% of primary breast tumors compared to normal breast tissue. Amplification of the AIB1 gene correlates with estrogen and progesterone positivity of primary breast tumors as well as with tumor size. It has been shown that AIB1 promotes the activity of the ER and estrogen-dependent growth of human MCF-7 breast cancer cells. Therefore, it has been hypothesized that AIB1 may contribute to the development of breast cancer.

Based on these data, **our hypothesis was that AIB1 determines activation or repression of a vast number of genes important for breast cancer growth. Our goal in this study was to identify these target genes.** To accomplish this goal, we generated human breast cancer cell lines (e.g. MCF-7) in which we specifically downregulated AIB1 levels utilizing tetracycline-regulatable ribozymes directed against AIB1 (tet-off system). Utilizing these cells, **we wanted to compare, after estrogen and growth factor stimulation, gene expression profiles from cells which have high AIB1 levels with gene expression profiles from cells that have significantly reduced AIB1 levels by microarray analysis, in order to identify AIB1 target genes that might have potential implications for breast cancer therapy.**

## **Proposal Body**

In the approved Statement of Work the following major task was outlined.

**Task 1 & 2:** Using tetracycline regulated ribozymes [13] we aimed to identify gene expression profiles and AIB1 target genes that might have potential implications for breast cancer therapy utilizing these cells by comparing gene expression profiles from cells which have high AIB1 levels with gene expression profiles from cells that have significantly reduced AIB1 levels by microarray analysis.

The following report summarizes the data obtained with the cDNA array analysis.

**Task 1:** The goal of our studies was to perform microarray analysis in order to identify gene expression patterns dependent on AIB1 levels and to identify AIB1 target genes that might have potential implications for breast cancer therapy.

For this we used cell lines in which we could regulate AIB1 levels using ribozymes [13].

#### A.) Description of the microarray technology used in this study

The type of array used was the GeneChip® Human Genome U95 set from *Affymetrix, Inc.* This array contains transcript coverage of the entire human genome. Using the U95 set allowed us to study the expression level of more than 60,000 full-length genes and ESTs (expression tagged sequences) using quantitative microarray technology. Represented sequences are derived from sequence clusters in Build 95 of the UniGene database (sequences in UniGene build 95 are from GenBank 113 and dbEST/10-02-99).

Critical specifications of the GeneChip® Human Genome U95 set:

- number of arrays in the set is five,
- the array format is a standard format,
- the feature size is 20 µM,
- the oligonucleotide probe length is a 25-mer,
- the probe pairs/ sequence is ~16
- Detection sensitivity is 1:100,000\* (\* As measured by detection in a comparative analysis between a complex target containing spiked control transcripts and a complex target with no spikes).
- Control sequences included:
  - Hybridization controls: *bioB*, *bioC*, *bioD* and *cre*
  - Poly-A controls: *da*, *lys*, *phe*, *thr*, and *trp*
  - Housekeeping/ Control Genes: GAPDH, beta-Actin, Transferrin receptor and ISGF-3

The DNA-Chip analyzer (dChip) [14] is a software package used for expression analysis of oligonucleotide arrays and high-level analysis procedures, such as hierarchical clustering. Hierarchical clustering uses standard statistical algorithms to arrange genes according to similarity in their pattern of gene expression [15]. Relationships among genes are expressed as a tree whose branch length represents the degree of similarity between genes. Groups of genes with similar expression patterns are put next to each other. Each sample or cell line can also be expressed as a tree and each branch also represents the degree of similarity between samples. For this analysis both samples and the genes were clustered together to form a single dendrogram. The left side of the dendrogram represents relationships among each genes, while the top of the dendrogram represents the relationships among the samples to each other.

The expression values for a gene across all samples are standardized (linearly scaled) to have mean 0 and standard deviation 1. These standardized values are used to calculate

correlations between genes and samples and serve as the basis of merging nodes. Joining two genes creates a node, and then a gene expression profile is computed for the node by averaging observation for the joined genes. Before the hierarchical clustering was performed, genes were initially excluded that showed little variation across the samples or their signal was absent from the majority of the samples. This process is termed filtering genes. This was the criteria we used to filter genes when the 20 samples were analyzed together:

- Variation across samples:  $0.5 < \text{standard deviation} / \text{mean} < 10.00$
- P (present) call % in the array used  $\geq 90\%$
- Replicate variation:  $0.00 < \text{Median}(\text{standard deviation} / \text{mean}) < 0.50$
- The expression level  $\geq 20.00$  in  $\geq 100\%$  samples

***Using these criteria, 169 genes out of a probe set of 12,600, satisfied this filtering criterion.*** These 169 genes were then analyzed, comparing the AIB1 ribozyme on/off cells with the different types of treatments. Her2 ribozyme cells [21] were used as a control to determine differences in the gene expression profile in the AIB1 ribozyme cells.

## B) Results of the microarray analysis

The result of the microarray analysis is graphically summarized in Fig.1 (see Appendix; on the bottom of the cluster image is the color scale: red represents the expression level above mean expression of a gene across all samples, white represents mean expression and blue represents lower than the mean expression).

The dChip program can categorize genes into “functional category classification.” Genes are classified according to molecular function, biological processes and cellular components using GeneOntology terms (<http://www.geneontology.org>) After hierarchical clustering is performed, dChip searches all branches with at least 4 functionally annotated genes to assess whether a local cluster is enriched by genes having a particular function.

Significant GeneOntology clusters found in our analysis are:

- Found 13 “RNA binding” genes in a 116-cluster (all: 328/8100, P value: 0.000791)  
In other words, this cluster has 116 functionally annotated genes (genes without annotation are not counted), of which 13 are RNA binding genes; considering there are all together 328 RNA binding genes in the 8100 functionally annotated genes on the array, this cluster is significantly enriched by RNA binding genes. A p value of 0.000791 is calculated)
- Found 12 “structural protein of ribosome” genes in a 116-cluster (all: 84/8100, P value: 0.000000)
- Found 5 “cell cycle regulator” genes in a 116-cluster (all: 71/8100, P value: 0.003391)
- Found 15 “structural protein” genes in a 116-cluster (all: 440/8100, P value: 0.001458)
- Found 6 “calcium binding” genes in a 116-cluster (all: 109/8100, P value 0.004637)

- Found 15 “transcriptional regulation” genes in a 116-cluster (all: 395/8100, P value: 0.000483)
- Found 16 “protein biosynthesis” genes in a 116-cluster (all: 175/8100, P value: 0.000000)
- Found 16 “cell cycle” genes in a 116-cluster (all: 544/8100, P value: 0.004499)
- Found 19 “biosynthesis” genes in a 116-cluster (all: 343/8100, P value: 0.000000)
- Found 18 “macromolecule biosynthesis” genes in a 116-cluster (all: 221/8100, P value: 0.000000)
- Found 7 “pathogenesis” genes in a 116-cluster (all: 104/8100, P value: 0.000697)
- Found 20 “protein metabolism and modification” genes in a 80-cluster (all: 1078/8100, P value: 0.003365)
- Found 6 “cell cycle control” genes in a 36-cluster (all: 363/8100, P value: 0.004836)
- Found 5 “mitotic cell cycle” genes in a 36-cluster (all: 253/8100, P value: 0.004878)
- Found 9 “cell proliferation” genes in a 36-cluster (all: 363/8100, P value: 0.000669)
- Found 4 “transcription factor” genes in a 7-cluster (all: 789/8100, P value: 0.002458)
- Found 15 “nucleic acid binding” genes in a 41-cluster (all: 1486/8100, P value: 0.004398)

Significant cytoband clusters found in our analysis:

- Found 15 “6p” genes in a 158-cluster (all: 441/11263, P value: 0.001340)
- Found 16 “6” genes in a 116-cluster (all: 684/11263, P value: 0.001683)
- Found 5 “6p21” genes in a 47-cluster (all: 263/11263, P value: 0.004604)
- Found 10 “19” genes in a 55-cluster (all: 723/11263, P value: 0.002340)

Genes found in the array study that are of particular interest in understanding what genes are regulated by the steroid receptor coregulator, AIB1, in a breast cancer cell line treated with different growth factors and hormones.

The hierarchical clustering analysis was able to distinguish the Her2 ribozyme cells from the AIB1 ribozyme cells having distinct gene expression patterns. The expression pattern of AIB1 ribozyme cells in comparison to Her2 ribozyme cells can be separated into 3 general sections. In the first section of significant genes, Her2 ribozyme cells generally have a lower expression level compared to AIB1 ribozyme cells.

1. *“survivin or baculoviral IAP repeat-containing 5”* – Survivin was of particular interest to examine from the first section of the dendrogram. Survivin is prominently expressed in human cancers of the lung, colon, pancreas, prostate and breast. Survivin is also expressed in ~50% of high-grade non-Hodgkin’s lymphomas, but not in low grade lymphomas [16]. Survivin or baculoviroal inhibitor of apoptosis protein repeat-containing 5 has a role in regulating apoptosis. Survivin is expressed in G2/M phase of the cell cycle. Survivin associates with microtubules of the mitotic spindle. If the interaction with microtubules is interrupted, the loss of survivin’s anti-apoptosis function and an increase in caspase-3 activity, a mechanism involved in cell death, occurs [17]. Survivin expression in the AIB1 ribozyme cells is significantly decreased compared to the Her2 ribozyme cells.

The second section, both AIB1 ribozyme cells and Her2 ribozyme cells have similar levels of expression. AIB1 (+/Her) or AIB1 treated with doxycycline and Heregulin was the least related to the other AIB1 ribozyme samples. 75 of 169 genes were significantly overexpressed in the AIB1 (+/Her) compared with all 19 other cell lines.

2. "*breast cancer metastasis-suppressor 1*" - Of particular interest to study further was the gene, breast cancer metastasis-suppressor 1 or BRMS-1. BRMS-1 has been found to reduce the metastatic capacity of human breast carcinoma cell lines [18]. AIB1 (+/Her) cell line expresses BRMS-1 at a high level compared to the other 19 cell lines. The significance of this differential expression needs to be investigated further.

The third and last section has the most differences in expression between the AIB1 and Her2 ribozyme cells. The Her2 ribozyme cells are all generally down regulated, while the AIB1 ribozyme cells have differential level of expression dependent on the AIB1 status. The AIB1 + cells generally seem to have no change in expression in these genes, while the AIB1 – cells generally have an increased expression in these genes.

3. "*breast carcinoma amplified sequence 1*" - Amplification in chromosome region 20q13 is associated with a large number of tumor types and aggressive tumor behavior. Also, increased copy number in the 20q13 region is found in 40% of breast cancer cell lines and 18% of primary breast tumors [19]. *NABC1* or *breast carcinoma amplified in sequence 1* was increased in expression in the AIB1(-) or ribozyme off cell lines compared with AIB1(+) or ribozyme on.
4. "*breast cancer 1, early onset*" – BRCA1 or breast cancer1 early onset is associated with genetic susceptibility to breast cancer. BRCA1 has been found to have a role in the maintaining genomic stability and transcriptional regulation. BRCA1 is located on chromosome 17q, an area frequently amplified in breast cancer [20]. Her2/neu (ERBB2) proto-oncogene is also located on 17q Her ribozyme cells all had a decrease in the expression of BRCA1 in comparison to the AIB1 ribozyme and did not have a significantly different level of expression within the treatments. The AIB1 ribozyme cells, however, expression of BRCA-1 was different depending the status of AIB1. The AIB1(-) ribozyme cells generally had a higher expression of BRCA1 compared to AIB1 (+) ribozyme cells.

## Key Research Accomplishments

- ✓ We found 169 genes (out of 12,600 screened) that fulfilled stringent screening criteria after Affymetrix microanalysis. These genes were analyzed, comparing the AIB1 ribozyme on/off cells with the different types of treatments. Her2 ribozyme cells were used as a control to determine differences in the gene expression profile in the AIB1 ribozyme cells.
- ✓ We identified 4 genes (survivin, breast cancer metastasis-suppressor 1, breast carcinoma amplified sequence 1, breast cancer 1, early onset) that were specifically regulated by AIB1 in human MCF-7 breast cancer cells and which might have potential implications for breast cancer therapy and are currently being studied further in the lab.

## **Reportable Outcomes**

List, H-J., Oh, A., and Riegel, A.T. "Finding AIB1 regulated target genes using microarray-based gene expression profiling." Manuscript in preparation.

## **Conclusions**

During this project, we wanted to identify AIB1 target genes that might be important for breast cancer growth. To accomplish this goal, we used human breast cancer cell lines in which we can specifically downregulate AIB1 levels utilizing tetracycline-regulatable ribozymes directed against AIB1 [13]. Utilizing these cells, we wanted to compare gene expression profiles from cells which have high AIB1 levels with gene expression profiles from cells that have significantly reduced AIB1 levels by microarray analysis, in order to identify AIB1 target genes that might have potential implications for breast cancer therapy.

During this project Affymetrix microarray studies in MCF-7 human breast cancer cells identified gene expression patterns that were different in cells which have high AIB1 levels from gene expression profiles from cells that have significantly reduced AIB1 levels. In addition, we were able to identify four AIB1 target genes that might have potential implications for breast cancer therapy. We anticipate that the results from this study will give valuable insights into the biological significance of AIB1 as well as its potential role as a therapeutic target in breast cancer.


## **References**

1. Horwitz, K.B., Jackson, T.A., Bain, D.L., Richer, J.K., Takimoto, G.S. and Tung, L. Nuclear receptor coactivators and corepressors. *Mol.Endocrinol.* 10:1167-1177, 1996.
2. Glass, C.K., Rose, D.P. and Rosenfeld, M.G. Nuclear receptor coactivators. *Curr.Opin.Cell Biol.* 9:222-232, 1997.
3. Anzick, A.L., Kononen, J., Walker, R.L., et al. AlB1, a steroid receptor coactivator amplified in breast and ovarian cancer. *Science* 277:965-968, 1997.
4. Guan, X.-Y., Xu, J., Anzick, S.L., Zhang, H., Trent, J.M. and Meltzer, P.S. Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within an amplified region at 20q11-q13.2 in breast cancer. *Canc.Res.* 56:3446-3450, 1996.

5. Chen, H., Lin, R.J., Schiltz, R.L., et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. *Cell* 90:569-580, 1997.
6. Li, H., Gomes, P.J. and Chen, J.D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. *Proc.Natl.Acad.Sci.USA* 94:8479-8484, 1997.
7. Takeshita, A., Cardona, G.R., Koibuchi, N., Suen, C.-S. and Chin, W.W. TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. *J.Biol.Chem.* 272:27629-27634, 1997.
8. Czubayko, F., Malerczyk, C. and Wellstein, A. Synthetic anti-pleiotrophin ribozymes are effective treatment for metastatic melanoma in mice, 2000 Manuscript in prep.
9. Czubayko, F., Riegel, A.T. and Wellstein, A. Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. *J Biol.Chem.* 269:21358-21363, 1994.
10. Czubayko, F., Liaudet-Coopman, E.D.E., Aigner, A., Tuveson, A.T., Berchem, G. and Wellstein, A. A secreted FGF-binding protein can serve as the angiogenic switch for human cancer. *Nature Med.* 3:1137-1140, 1997.
11. Schulte, A.M. and Wellstein, A. Pleiotrophin and related molecules. In: *Tumour Angiogenesis*, edited by R. Bicknell, C.M. Lewis and N. Ferrara. Oxford, New York, Tokyo: Oxford University Press, 1997, p. 273-289.
12. Juhl H, Downing SG, Wellstein A, Czubayko F. HER-2/neu is rate-limiting for ovarian cancer growth. (1997) Conditional depletion of HER-2/neu by ribozyme targeting. *J Biol Chem.* 272, 29482-6.
13. List, H.-J., Lauritsen, K., Reiter, R., Wellstein, A. and Riegel, A.T. (2001) Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. *J. Biol. Chem.* 276, 23763-23768.
14. Li, C., DNA-Chip Analyzer (dChip) User's Manual, W.H. Wong, Editor.<http://biosun1.harvard.edu/compulab/dchip/manual.htm>.
15. Eisen, M.B., et al. (1998) Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci U S A* 95, 14863-8.
16. Ambrosini, G., C. Adida, and D.C. Altieri (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. *Nat Med* 3, 917-21.

17. Li, F., et al., Control of apoptosis and mitotic spindle checkpoint by survivin (1998) Nature 396, 580-4.
18. Seraj, M.J., et al.(2000) Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 60, 2764-9.
19. Collins, C., et al. (1998) Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A 95, 8703-8.
20. Plummer, S.J., et al., Localization of a growth suppressor activity in MCF7 breast cancer cells to chromosome 17q24-q25.PG - 2339-45. Oncogene, 1997. 14(19).
21. List, H-J., Czubayko, F., and Wellstein, A. Genration of regulable Her2 ribozyme cell lines in breast cancer. Manuscript in preparation.

# Figure 1



**Figure 1** – The final dendrogram containing the 169 genes found to be significantly expressed between 20 samples. (A.), each row in the dendrogram represents the expression level of a gene, while each column represents the expression pattern of the different genes in each sample. Using hierarchical clustering, the dCHIP analysis software was able to group each gene and sample based on degrees of similarity in expression. The genes are not grouped according to any functional similarity. A portion of the final dendrogram was enlarged. (B.), represents a hierarchical tree of how the samples grouped together based on their gene expression profile. The Her2 ribozyme cells were different from the AIB1 ribozyme cells. Within the AIB1 ribozyme group, AIB1 (+/- Her) or ribozyme off and heregulin treated cells had a gene expression profile that separated it from the other growth factor treated AIB1(+) cells. AIB1 (-/E2, IGF, -, DHT) or ribozyme on, had little differences in their gene expression profiles. (C.), represents a color scale: red represents the expression level above the mean expression of a gene, white represents mean expression, and blue represents a level lower than the mean expression level.